Table 2.
Compliance, treatment tolerance, and treatment response to perioperative chemotherapy
| Preoperative chemotherapy (N=171) | Postoperative chemotherapy (N=115) | ||
|---|---|---|---|
| Administration of chemotherapy | |||
| Number of cycles | |||
| 1 | 6 (4%) | 7 (6%) | |
| 2 | 1 (1%) | 10 (9%) | |
| 3 | 8 (5%) | 5 (4%) | |
| 4 | 7 (4%) | 5 (4%) | |
| 5 | 6 (4%) | 8 (7%) | |
| 6 | 143 (84%) | 80 (70%)* | |
| Median (range) | 6 (1–6) | 6 (1–8) | |
| Relative dose intensity | |||
| 5-fluorouracil (%) | 92·3% (50·0 to 111·3) | 82·0% (36·9 to 112·2) | |
| Oxaliplatin (%) | 92·1% (54·6 to 106·0) | 79·1% (0·0 to 106·5) | |
| Dose reduction(s) | 58 (34%) | 69 (60%) | |
| Delayed cycle(s) | 75 (44%) | 73 (64%) | |
| Response to preoperative chemotherapy (RECIST)† | |||
| Complete response | 4 (3%) | .. | |
| Partial response | 63 (40%) | .. | |
| Stable disease | 60 (38%) | .. | |
| Progressive disease | 11 (7%) | .. | |
| After 3–4 cycles | 7‡ (64%) | .. | |
| After 6 cycles | 4§ (36%) | .. | |
| Not assessable | 21 (13%) | .. | |
| Ineligible | 5 (24%) | .. | |
| Benign lesion | 2 (10%) | .. | |
| <3 cycles | 10 (48%) | .. | |
| No follow-up measurements | 4 (19%) | .. | |
| Sum of the largest diameters of lesions on imaging | |||
| At entry (mm) | 50 (20 to 255) | .. | |
| After preoperative chemotherapy (mm) | 33 (0 to 230) | .. | |
| Relative reduction (%) | −25·6% (−100 to 228·6) | .. | |
Data are number (%) or median (range). RECIST=response criteria in solid tumours.13
*
Including one patient who received seven cycles and one who received eight cycles.
†
Assessed in patients with at least one baseline lesion 20 mm or more (N=159).
‡
Three of seven patients underwent resection, one further patient who is not eligible for RECIST response assessment progressed after three cycles and did not undergo resection.
§
One of four patients underwent resection.